Accelerated approval of oncology products: a decade of experience.
暂无分享,去创建一个
Richard Pazdur | P. Keegan | R. Pazdur | R. Dagher | John R. Johnson | G. Williams | Ramzi Dagher | Patricia Keegan | John Johnson | Grant Williams
[1] R. Pazdur,et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] G. Giaccone,et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Powles,et al. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. , 1997, European journal of cancer.
[4] C. Spurr,et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. , 1991, The New England journal of medicine.
[5] S. Krown,et al. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Labianca,et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.
[7] Richard Pazdur,et al. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. , 2003, The oncologist.
[8] R. Wittes,et al. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Tattersall,et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. , 1987, The New England journal of medicine.
[10] R. Pazdur,et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. , 2003, The oncologist.
[11] Christian Jacques,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.
[12] D. Giannarelli,et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] G. Sledge,et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Alison Martin,et al. U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. , 2002, The oncologist.
[15] R. Pazdur,et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[17] Richard Pazdur,et al. End points and United States Food and Drug Administration approval of oncology drugs. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Mark Rothmann,et al. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] D Guthrie,et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Pazdur,et al. Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. , 2002, The oncologist.
[21] X. H. Chen,et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[23] J. Carmichael,et al. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer , 1990, The Lancet.
[24] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Pazdur,et al. United States Food and Drug Administration Drug Approval Summary , 2004, Clinical Cancer Research.
[26] S. Salmon,et al. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] G. Tucker,et al. Clinical Measurement in Drug Evaluation , 1991 .
[28] S. Hirschfeld,et al. FDA drug approval summaries: oxaliplatin. , 2004, The oncologist.
[29] M. Stockler,et al. Chemotherapy for metastatic breast cancer--when is enough enough? , 1997, European journal of cancer.
[30] J. Berlin,et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.